Lacosamide G.L. Pharma (Lacosamide)

• Lacosamide is an anticonvulsant used in the management of seizure disorders.
• Partial‑onset seizures: reduces the frequency of focal seizure episodes in patients with uncontrolled seizures.
• Adjunctive therapy in epilepsy: provides additional seizure control when combined with other antiepileptic drugs.
• Refractory focal epilepsy: improves seizure management in patients not adequately controlled by prior therapies.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes, stabilizing hyperexcitable neuronal membranes and decreasing repetitive neuronal firing. By selectively targeting the sodium channel’s slow inactivation pathway, it reduces neuronal excitability without markedly affecting normal conduction, thereby contributing to seizure control. This action is dose‑dependent and contributes to the drug’s efficacy as an adjunctive antiepileptic agent. The effect is observed across a broad range of neuronal subtypes involved in epileptogenesis.

Lacosamide may be associated with several adverse reactions, ranging from common to rare but serious events.

Common Side Effects

• Dizziness
• Nausea
• Headache
• Fatigue

Serious or Rare Side Effects

• Cardiac arrhythmias (e.g., PR interval prolongation)
• Severe skin reactions (e.g., Stevens‑Johnson syndrome)
• Suicidal thoughts or behavior

• When prescribing lacosamide, clinicians should consider several precautionary measures to ensure safe use.
• Renal impairment: adjust dose in patients with reduced kidney function.
• Hepatic dysfunction: monitor liver enzymes and consider dose adjustment.
• Cardiac conduction: assess ECG for PR interval prolongation before initiating therapy.
• Concomitant antiepileptic drugs: evaluate for additive CNS depression.
• Pregnancy and lactation: use only if potential benefit justifies potential risk; data limited.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Lacosamide can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may significantly reduce lacosamide plasma concentrations.
• Concomitant use with other sodium channel blockers (e.g., lamotrigine, oxcarbazepine): may increase risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): may require INR monitoring.
• Alcohol: may enhance CNS depressive effects.
• Other antiepileptic drugs: may require dose adjustments based on therapeutic response.